{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T11:18:19Z","timestamp":1792840699456,"version":"4.5.0"},"reference-count":16,"publisher":"Japanese Society of Internal Medicine","issue":"21","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intern. Med."],"published-print":{"date-parts":[[2019,11,1]]},"DOI":"10.2169\/internalmedicine.2995-19","type":"journal-article","created":{"date-parts":[[2019,7,9]],"date-time":"2019-07-09T22:03:27Z","timestamp":1562709807000},"page":"3167-3171","source":"Crossref","is-referenced-by-count":7,"title":["Rheumatoid Arthritis Complicated with Nasal Septum Perforation Due to Methotrexate-associated Lymphoproliferative Disorder"],"prefix":"10.2169","volume":"58","author":[{"given":"Ryuki","family":"Sakaguchi","sequence":"first","affiliation":[{"name":"Department of Rheumatology, Japan Community Healthcare Organization, Isahaya General Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keita","family":"Fujikawa","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Japan Community Healthcare Organization, Isahaya General Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Momoko","family":"Okamoto","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Japan Community Healthcare Organization, Isahaya General Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emi","family":"Matsuo","sequence":"additional","affiliation":[{"name":"Department of Hematology, Japan Community Healthcare Organization, Isahaya General Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kohei","family":"Matsumoto","sequence":"additional","affiliation":[{"name":"Department of Otolaryngology, Japan Community Healthcare Organization, Isahaya General Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomohisa","family":"Uchida","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Japan Community Healthcare Organization, Isahaya General Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kawashiri","family":"Shin-ya","sequence":"additional","affiliation":[{"name":"Department of Immunology and Rheumatology, Graduate School of Biomedical Sciences, Nagasaki University, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masahiro","family":"Nakashima","sequence":"additional","affiliation":[{"name":"Department of Tumor and Diagnostic Pathology, Atomic Bomb Disease Institute, Nagasaki University, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akinari","family":"Mizokami","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Japan Community Healthcare Organization, Isahaya General Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atsushi","family":"Kawakami","sequence":"additional","affiliation":[{"name":"Department of Immunology and Rheumatology, Graduate School of Biomedical Sciences, Nagasaki University, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"962","reference":[{"key":"1","unstructured":"1. Ellman MH, Hurwitz H, Thomas C, Kozloff M. Lymphoma developing in a patient with rheumatoid arthritis taking low dose weekly methotrexate. J Rheumatol 18: 1741-1743, 1991."},{"key":"2","unstructured":"2. Gaulard PSS, Harris NL, Jaffe ES, et al. Other iatrogenic immunodeficiency-associated lymphoproliferative disorders. In: WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. 4th ed. Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Eds. IARC, Lyon, 2008: 350-351."},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Kameda T, Dobashi H, Miyatake N, et al. Association of higher methotrexate dose with lymphoproliferative disease onset in rheumatoid arthritis patients. Arthritis Care Res (Hoboken) 66: 1302-1309, 2014.","DOI":"10.1002\/acr.22306"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Kaneko Y. Methotrexate-associated lymphoproliferative disorder. Nihon Rinsho Men&apos;eki Gakkai kaishi (Japanese Journal of Clinical Immunology) 40: 174-178, 2017 (in Japanese, Abstract in English).","DOI":"10.2177\/jsci.40.174"},{"key":"5","unstructured":"5. Ichikawa A, Arakawa F, Kiyasu J, et al. Methotrexate\/iatrogenic lymphoproliferative disorders in rheumatoid arthritis: histology, Epstein-Barr virus, and clonality are important predictors of disease progression and regression. Eur J Haematol 91: 20-28, 2013."},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Saito S, Kaneko Y, Yamaoka K, Tokuhira M, Takeuchi T. Distinct patterns of lymphocyte count transition in lymphoproliferative disorder in patients with rheumatoid arthritis treated with methotrexate. Rheumatology (Oxford) 56: 940-946, 2017.","DOI":"10.1093\/rheumatology\/kex002"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Tokuhira M, Watanabe R, Nemoto T, et al. Clinicopathological analyses in patients with other iatrogenic immunodeficiency-associated lymphoproliferative diseases and rheumatoid arthritis. Leuk Lymphoma 53: 616-623, 2012.","DOI":"10.3109\/10428194.2011.625101"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Abbondanzo SL, Wenig BM. Non-Hodgkin&apos;s lymphoma of the sinonasal tract. A clinicopathologic and immunophenotypic study of 120 cases. Cancer 75: 1281-1291, 1995.","DOI":"10.1002\/1097-0142(19950315)75:6<1281::AID-CNCR2820750610>3.0.CO;2-I"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Wooten MD, Jasin HE. Vasculitis and lymphoproliferative diseases. Semin Arthritis Rheum 26: 564-574, 1996.","DOI":"10.1016\/S0049-0172(96)80044-8"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Foley JF, Linder J, Koh J, Severson G, Purtilo DT. Cutaneous necrotizing granulomatous vasculitis with evolution to T cell lymphoma. Am J Med 82: 839-844, 1987.","DOI":"10.1016\/0002-9343(87)90026-X"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Katsuyama T, Sada KE, Yan M, et al. Prognostic factors of methotrexate-associated lymphoproliferative disorders associated with rheumatoid arthritis and plausible application of biological agents. Mod Rheumatol 27: 773-777, 2017.","DOI":"10.1080\/14397595.2016.1259714"},{"key":"12","unstructured":"12. Lopez-Olivo MA, Tayar JH, Martinez-Lopez JA, et al. Risk of malignancies in patients with rheumatoid arthritis treated with biologic therapy: a meta-analysis. JAMA 308: 898-908, 2012."},{"key":"13","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1016\/j.jbspin.2015.07.009","volume":"83","author":"C Mourgues","year":"2016","unstructured":"13. Mourgues C, Henquell C, Tatar Z, et al. Monitoring of Epstein- Barr virus (EBV)\/cytomegalovirus (CMV)\/varicella-zoster virus (VZV) load in patients receiving tocilizumab for rheumatoid arthritis. Joint Bone Spine 83: 412-415, 2016.","journal-title":"Joint Bone Spine","ISSN":"https:\/\/id.crossref.org\/issn\/1297-319X","issn-type":"print"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Balandraud N, Texier G, Massy E, et al. Long term treatment with abatacept or tocilizumab does not increase Epstein-Barr virus load in patients with rheumatoid arthritis - A three years retrospective study. PLoS One 15: 12: e0171623, 2017.","DOI":"10.1371\/journal.pone.0171623"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Ogawa J, Harigai M, Akashi T, et al. Exacerbation of chronic active Epstein-Barr virus infection in a patient with rheumatoid arthritis receiving humanised anti-interleukin-6 receptor monoclonal antibody. Ann Rheum Dis 65: 1667-1669, 2006.","DOI":"10.1136\/ard.2006.054197"},{"key":"16","unstructured":"16. Inui Y, Matsuoka H, Yakushijin K, et al. Methotrexate-associated lymphoproliferative disorders: management by watchful waiting and observation of early lymphocyte recovery after methotrexate withdrawal. Leuk Lymph 56: 3045-3051, 2015."}],"container-title":["Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/58\/21\/58_2995-19\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,2]],"date-time":"2019-11-02T03:43:21Z","timestamp":1572666201000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/58\/21\/58_2995-19\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11,1]]},"references-count":16,"journal-issue":{"issue":"21","published-print":{"date-parts":[[2019]]}},"URL":"https:\/\/doi.org\/10.2169\/internalmedicine.2995-19","relation":{},"ISSN":["0918-2918","1349-7235"],"issn-type":[{"value":"0918-2918","type":"print"},{"value":"1349-7235","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,11,1]]}}}